Dovitinib in Neuroendocrine Tumors

Summary

This study is being conducted to evaluate whether the investigational drug Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors. This study will also further evaluate the safety of this drug.

Timeline

Start

2012-06

Primary completion

2016-03

Completion

2016-04-11

Drugs

Indications